News

The phase 3 PEAK trial showed that combining bezuclastinib, a selective oral KIT inhibitor, with sunitinib significantly improves outcomes in patients with advanced gastrointestinal stromal tumors (GIST) who have progressed after first-line therapy. The combination reduced the risk of disease progression or death by 50%, with median progression-free survival of 16.5 months versus 9.2 months […]

The Phase 1/2a BLUESTAR trial showed promising results for puxitatug samrotecan (Puxi-Sam), a B7-H4-targeting antibody-drug conjugate developed for advanced gynecologic cancers. The drug delivers a topoisomerase 1 inhibitor directly to tumor cells expressing B7-H4, a protein commonly found in endometrial and ovarian cancers. At the recommended 2.4 mg/kg dose, Puxi-Sam achieved an objective response rate

The phase 1 NEXUS-01 trial demonstrated encouraging activity for LY4052031, a next-generation Nectin-4-targeting antibody-drug conjugate (ADC) for metastatic urothelial carcinoma. Designed to overcome resistance to enfortumab vedotin (EV), LY4052031 uses a novel topoisomerase 1 inhibitor payload. Among heavily pretreated patients previously exposed to EV, the drug achieved an objective response rate (ORR) of 33% and

The phase 3 SUCCESSOR-2 trial showed that adding mezigdomide, an oral CELMoD, to carfilzomib and dexamethasone significantly improved outcomes for patients with relapsed or refractory multiple myeloma. The triplet regimen doubled median progression-free survival to 18.0 months compared with 8.3 months for carfilzomib and dexamethasone alone, reducing the risk of disease progression or death by